Orlanz Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Net Worth -21.80%
- Total Assets -7.41%
About Orlanz Formulations
Orlanz Formulations Private Limited (OFPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 September 2020 (Four years and four months 16 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vishal Rajyaguru, Jogi Ramaniklal, Hiren Jayrambhai, and One other member serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290GJ2020PTC116609
-
Company No.
116609
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Sep 2020
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Orlanz Formulations?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hiren Jayrambhai
|
Director | 17-Sep-2020 | Current |
|
Bhaveshkumar Vyas
|
Director | 17-Sep-2020 | Current |
|
Vishal Rajyaguru
|
Director | 17-Sep-2020 | Current |
|
Jogi Ramaniklal
|
Director | 17-Sep-2020 | Current |
Financial Performance of Orlanz Formulations.
Orlanz Formulations Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 21.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orlanz Formulations?
In 2021, Orlanz Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
4Care Lifescience Private LimitedJogi Ramaniklal and Bhaveshkumar Vyas are mutual person
-
Avixus Lifescience Private LimitedVishal Rajyaguru is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Orlanz Formulations?
Orlanz Formulations has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orlanz Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orlanz Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.